Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VTX 803

Next Previous
Search
Drug Profile

VTX 803

Alternative Names: VTX-803

Latest Information Update: 29 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vivet Therapeutics
  • Developer CIMA- Universidad de Navarra; Vivet Therapeutics
  • Class Gene therapies; Hepatoprotectants
  • Mechanism of Action Gene transference; Multidrug resistance protein 3 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Intrahepatic cholestasis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Intrahepatic cholestasis

Most Recent Events

  • 29 Apr 2024 VTX 802 is still in preclinical trial for Intrahepatic cholestasis in France and Spain (Parenteral) (Vivet Therapeutics pipeline, April 2024)
  • 28 Nov 2023 No recent reports of development identified for preclinical development in Intrahepatic-cholestasis in France (Parenteral)
  • 28 Nov 2023 No recent reports of development identified for preclinical development in Intrahepatic-cholestasis in Spain (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top